These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 7735336)

  • 1. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M; Maccario M; Grottoli S; Oleandri SE; Boffano GM; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G; Grugni G; Morabito F
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S; Procopio M; Maccario M; Zini M; Oleandri SE; Tassone F; Valcavi R; Ghigo E
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L; Marziani E; Manzoni P; Arvat E; Valetto MR; Gianotti L; Ghigo E; Chiumello G
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
    Ghigo E; Arvat E; Gianotti L; Nicolosi M; Valetto MR; Avagnina S; Bellitti D; Rolla M; Müller EE; Camanni F
    Biol Psychiatry; 1994 Nov; 36(10):689-95. PubMed ID: 7880938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.
    Giustina A; Bossoni S; Bodini C; Ferrari C; Pizzocolo G; Scalvini T; Schettino M; Wehrenberg WB
    Horm Res; 1991; 35(3-4):99-103. PubMed ID: 1806475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children.
    Bellone J; Ghigo E; Procopio M; Arvat E; Valente F; Boffano GM; Maccario M; Dentelli P; Camanni F
    Panminerva Med; 1993 Mar; 35(1):1-4. PubMed ID: 8316397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.
    Borges MH; Castro RC; Kater CE; Lengyel AM
    Braz J Med Biol Res; 1993 Nov; 26(11):1191-200. PubMed ID: 7907904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.
    Ghigo E; Bellone J; Aimaretti G; Bellone S; Loche S; Cappa M; Bartolotta E; Dammacco F; Camanni F
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3323-7. PubMed ID: 8784091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E; Cappa M; Casanueva FF; Dieguez C; Ghigo E; Nicolosi M; Valcavi R; Zini M
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E; Goffi S; Nicolosi M; Arvat E; Valente F; Mazza E; Ghigo MC; Camanni F
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E; Gianotti L; Ragusa L; Valetto MR; Cappa M; Aimaretti G; Ramunni J; Grottoli S; Camanni F; Ghigo E
    Dementia; 1996; 7(5):288-92. PubMed ID: 8872421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity?
    Ghigo E; Procopio M; Maccario M; Bellone J; Arvat E; Campana S; Boghen MF; Camanni F
    Horm Metab Res; 1993 Jun; 25(6):305-8. PubMed ID: 8344645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.